Although analysis of cost effectiveness has not been performed, E

Although analysis of cost effectiveness has not been performed, ERCP has drawbacks in terms of complications. Chromosome 7 contains genes for the epidermal growth factor, c-Met, and interleukin-6, which have been implicated with bile duct

carcinogenesis,25 so that cancers may develop later in these patients, and further study is needed. DeHaan et al.,26 in a study of paraffin-embedded cholangiocarcinoma from PSC patients, observed polysomy Pexidartinib solubility dmso not only in CCA but also in areas that had been interpreted as high-grade dysplasia (HGD).26 HGD of the bile ducts of PSC patients is the morphologic precursor to frank CCA. HGD has been observed to have a level of genetic abnormality by FISH that is similar to in situ and invasive carcinoma in other settings such as Barrett’s esophagus.27, 28 It is likely that the development of CCA in PSC patients is preceded by one or more foci of HGD. It may take months or years for areas of HGD in PSC patients to progress to CCA, and in some cases this progression may not occur. The finding of polysomy in HGD in PSC patients indicates that this genetic alteration is not absolutely specific for CCA in PSC patients. We believe that when polysomy is observed in patients with other

concerning findings (such as a dominant stricture), it has a high positive predictive value for the presence of CCA. However, http://www.selleckchem.com/products/gsk1120212-jtp-74057.html when such additional clinical findings are not present, the positive predictive value of polysomy for CCA is significantly lower. Polysomy in PSC patients without additional concerning clinical findings should be interpreted more cautiously. Its occurrence in such patients may indicate that they are at higher risk of developing CCA but may not actually have frank CCA. Our results indicate that FISH testing should not be used

as a screening modality in unselected PSC patients undergoing ERCP. However, in patients with clinical or laboratory suspicion of CCA, such as weight loss, abdominal pain, dominant stricture, or high CA 19-9, these tests can be helpful. The analysis of our findings suggests the following guidelines: If a positive trisomy or tetrasomy are obtained without evidence of CCA on imaging, cross-sectional imaging should be repeated 3 months later. If other features such as dominant stricture, prominent 上海皓元 CA 19-9 elevation, or mass are present, cross-sectional imaging and ERCP should repeated at 3 months. These patients should thereafter be followed clinically as are other PSC patients with CA 19-9 levels and ultrasound at 6 months and then annually, as recently shown to be effective.9 The presence of FISH trisomy or tetrasomy does not indicate a high likelihood of CCA. If patients with positive polysomy are not found to have CCA at the initial examination, we would repeat the evaluation after 3 months. According to our Kaplan Meier analysis, patients with positive polysomy very rarely die within 3 months.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>